Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lifeward Ltd.LFWD · Entity 7620 | Director | March 25, 2026 | March 27, 2026 |
| ORAMED PHARMACEUTICALS INC.ORMP · Entity 6311 | Director · Chief Scientific Officer | September 24, 2026 | September 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lifeward Ltd.
Report date March 25, 2026 · Filed March 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, no par value per shareSEC Table I · non-derivative | Direct | 7,657 |
Reported balance
After 2026-03-25 transaction · row 1
1 source rowRow 1 · 2026-03-25 · Grant · Acquired 7,657 · Balance 7,657 F1: Represents 7,657 ordinary shares, no par value per share, issuable upon the vesting of restricted stock units ("RSUs") granted on March 25, 2026 (the "Grant Date") under the Issuer's 2025 Incentive Compensation Plan. The RSUs vest ratably in four equal quarterly installments starting three months from the Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 7,657 ordinary shares, no par value per share, issuable upon the vesting of restricted stock units ("RSUs") granted on March 25, 2026 (the "Grant Date") under the Issuer's 2025 Incentive Compensation Plan. The RSUs vest ratably in four equal quarterly installments starting three months from the Grant Date.
ORAMED PHARMACEUTICALS INC.
Report date September 24, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,550,554 |
Ending reported balance
After 2026-09-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-24 · Grant · Acquired 208,125 · Balance 1,341,263 F1: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. Row 2 · 2026-09-24 · Grant · Acquired 209,291 · Balance 1,550,554 F2: On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 209,291 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the "Plan"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.16 · Expires 2029-09-11 | Direct | 0 |
Reported balance
After 2026-09-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-24 · Disposition to issuer · Disposed 104,000 · Balance 0 F1: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F3: The canceled option provided for vesting in 4 equal installments of 26,000 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 · Expires 2030-01-08 | Direct | 0 |
Reported balance
After 2026-09-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-24 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F4: The canceled option provided for vesting in 4 equal installments as follows: 25,000 shall vest on each of December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.77 · Expires 2027-06-30 | Direct | 0 |
Reported balance
After 2026-09-24 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-24 · Disposition to issuer · Disposed 69,999 · Balance 0 F1: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F5: The canceled option provided for vesting in 3 equal installments of 23,333 on each of December 31, 2017, December 31, 2018 and December 31, 2019. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.14 · Expires 2028-01-31 | Direct | 0 |
Reported balance
After 2026-09-24 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-24 · Disposition to issuer · Disposed 47,000 · Balance 0 F1: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F6: The canceled option provided for vesting in 4 equal installments of 11,750 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.40 · Expires 2031-02-03 | Direct | 0 |
Reported balance
After 2026-09-24 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-24 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F7: The canceled option provided for vesting in 4 equal installments as follows: 25,000 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.89 · Expires 2032-01-03 | Direct | 0 |
Reported balance
After 2026-09-24 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-24 · Disposition to issuer · Disposed 72,000 · Balance 0 F1: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F8: The canceled option provided for vesting in 4 equal installments as follows: 18,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.
F2: On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 209,291 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the "Plan"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan.
F3: The canceled option provided for vesting in 4 equal installments of 26,000 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022.
F4: The canceled option provided for vesting in 4 equal installments as follows: 25,000 shall vest on each of December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023.
F5: The canceled option provided for vesting in 3 equal installments of 23,333 on each of December 31, 2017, December 31, 2018 and December 31, 2019.
F6: The canceled option provided for vesting in 4 equal installments of 11,750 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022.
F7: The canceled option provided for vesting in 4 equal installments as follows: 25,000 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024.
F8: The canceled option provided for vesting in 4 equal installments as follows: 18,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2026 Filed Sep 25, 2026 20:30 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Disposition to issuerStock option (right to buy) · Derivative | 72,000 | Not disclosed Strike: $13.89 | Not disclosed |
DisclosureSEC source: 0001213900-26-103536 · ownership.xml · derivative · entry 8 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 72,000 shares Expires 2032-01-03 F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F8 · derivative.exercise_date: The canceled option provided for vesting in 4 equal installments as follows: 18,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:30 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Disposition to issuerStock option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $10.40 | Not disclosed |
DisclosureSEC source: 0001213900-26-103536 · ownership.xml · derivative · entry 7 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2031-02-03 F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F7 · derivative.exercise_date: The canceled option provided for vesting in 4 equal installments as follows: 25,000 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:30 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Disposition to issuerStock option (right to buy) · Derivative | 47,000 | Not disclosed Strike: $8.14 | Not disclosed |
DisclosureSEC source: 0001213900-26-103536 · ownership.xml · derivative · entry 6 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,000 shares Expires 2028-01-31 F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F6 · derivative.exercise_date: The canceled option provided for vesting in 4 equal installments of 11,750 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:30 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Disposition to issuerStock option (right to buy) · Derivative | 69,999 | Not disclosed Strike: $7.77 | Not disclosed |
DisclosureSEC source: 0001213900-26-103536 · ownership.xml · derivative · entry 5 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 69,999 shares Expires 2027-06-30 F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F5 · derivative.exercise_date: The canceled option provided for vesting in 3 equal installments of 23,333 on each of December 31, 2017, December 31, 2018 and December 31, 2019. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:30 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Disposition to issuerStock option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $4.80 | Not disclosed |
DisclosureSEC source: 0001213900-26-103536 · ownership.xml · derivative · entry 4 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2030-01-08 F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F4 · derivative.exercise_date: The canceled option provided for vesting in 4 equal installments as follows: 25,000 shall vest on each of December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:30 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Disposition to issuerStock option (right to buy) · Derivative | 104,000 | Not disclosed Strike: $3.16 | Not disclosed |
DisclosureSEC source: 0001213900-26-103536 · ownership.xml · derivative · entry 3 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 104,000 shares Expires 2029-09-11 F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. F3 · derivative.exercise_date: The canceled option provided for vesting in 4 equal installments of 26,000 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:30 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 209,291 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-103536 · ownership.xml · nonDerivative · entry 2 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,550,554 F2 · price: On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 209,291 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the "Plan"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:30 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 208,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-103536 · ownership.xml · nonDerivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,341,263 F1 · price: On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors. Read SEC document |
| March 30, 2026 Filed Mar 31, 2026 20:10 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Tax withholdingCommon Stock | 435,084 | $3.31 | $1,440,128.04 |
DisclosureSEC source: 0001213900-26-037446 · ownership.xml · nonDerivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,133,138 F1 · shares: Represents shares of common stock, par value $0.012 per share ("Common Stock"), of the Issuer used to satisfy tax withholding obligations attributable to the vesting and settlement of Restricted Stock Units, which were valued at the closing price of the Issuer's Common Stock on the date immediately prior to the vesting date, equal to $3.31 per share. F1 · price: Represents shares of common stock, par value $0.012 per share ("Common Stock"), of the Issuer used to satisfy tax withholding obligations attributable to the vesting and settlement of Restricted Stock Units, which were valued at the closing price of the Issuer's Common Stock on the date immediately prior to the vesting date, equal to $3.31 per share. Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 20:37 UTC | Lifeward Ltd. LFWD · Entity 7620 | GrantOrdinary Shares, no par value per share | 7,657 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-26-001812 · ownership.xml · nonDerivative · entry 1 Kidron Miriam · CIK 0001409232 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,657 F1 · shares: Represents 7,657 ordinary shares, no par value per share, issuable upon the vesting of restricted stock units ("RSUs") granted on March 25, 2026 (the "Grant Date") under the Issuer's 2025 Incentive Compensation Plan. The RSUs vest ratably in four equal quarterly installments starting three months from the Grant Date. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 21:46 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 119,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-031015 · ownership.xml · nonDerivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,568,222 F1 · shares: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer. F1 · price: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer. Read SEC document |
| January 22, 2026 Filed Jan 29, 2026 21:05 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionPerformance Stock Units · Derivative | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-009478 · ownership.xml · derivative · entry 2 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting. F2 · derivative.exercise_date: Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria. F2 · derivative.expiration_date: Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria. Read SEC document |
| January 22, 2026 Filed Jan 29, 2026 21:05 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionCommon Stock | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-009478 · ownership.xml · nonDerivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,448,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting. F1 · price: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting. Read SEC document |
| January 14, 2026 Filed Jan 21, 2026 21:30 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GiftCommon Stock | 86,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-006215 · ownership.xml · nonDerivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,343,498 F1 · kind: This transaction represents a charitable donation and is not a market transaction, thus no price has been reported. No value was received for the donated shares. The Reporting Person is not affiliated with, and has no control over, the donee. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:21 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantPerformance Stock Units · Derivative | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-001279 · ownership.xml · derivative · entry 3 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires not disclosed F3 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria. F3 · derivative.exercise_date: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria. F3 · derivative.expiration_date: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:21 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 115,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-001279 · ownership.xml · nonDerivative · entry 2 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,429,664 F2 · shares: Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer. F2 · price: Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:21 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 121,331 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-001279 · ownership.xml · nonDerivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,314,664 F1 · shares: Represents Restricted Stock Units ("RSUs") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer. F1 · price: Represents Restricted Stock Units ("RSUs") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 21:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 66,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-012241 · ownership.xml · nonDerivative · entry 3 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,193,333 F3 · shares: Represents shares issued on settlement of PSUs previously granted on February 3, 2025 that vested on February 11, 2025 based on the achievement of the applicable performance criteria. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 21:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 52,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-012241 · ownership.xml · nonDerivative · entry 2 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,126,666 F2 · shares: Represents shares issued on settlement of PSUs previously granted on January 2, 2025 that vested on February 11, 2025 based on the achievement of the applicable performance criteria. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 21:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 74,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-012241 · ownership.xml · nonDerivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,074,666 F1 · shares: Represents shares issued on settlement of performance stock units ("PSUs") previously granted on January 4, 2024 that vested on February 11, 2025 based on the achievement of the applicable performance criteria. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:10 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 207,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-25-001169 · ownership.xml · nonDerivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,666 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in quarterly installments of approximately 17,250 over a three year period starting January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 21:30 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-24-095930 · ownership.xml · nonDerivative · entry 1 Kidron Miriam · CIK 0001409232 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 793,666 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest on November 7, 2024. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 21:43 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 295,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-001154 · doc4.xml · nonDerivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 763,666 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in equal quarterly installments of 24,625 over a three year period starting January 8, 2024. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| May 26, 2023 Filed May 31, 2023 21:10 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 53,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-033143 · doc4.xml · nonDerivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 468,166 F1 · price: Restricted Stock Units ("RSUs") granted in April 2023 and vested upon achievement of certain performance conditions. The RSUs converted into Issuer's common stock on a one-for-one basis. Read SEC document |
| April 17, 2023 Filed Apr 20, 2023 10:00 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 213,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-024937 · doc4.xml · nonDerivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 414,666 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in equal quarterly installments of 17,750 over a three year period starting May 1, 2023. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 21:20 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | SaleCommon Stock | 100,000 | $2.01 | $201,000.00 |
DisclosureSEC source: 0001209191-23-018952 · doc4.xml · nonDerivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,666 F1 · price: These shares were sold to a company owned solely by Nadav Kidron, a director and the president and chief executive officer of the Issuer, and the Reporting Person used the proceeds in connection with a personal tax payment. Read SEC document |
| July 28, 2022 Filed Aug 2, 2022 00:00 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 84,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-043769 · doc4.xml · nonDerivative · entry 2 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,666 F2 · price: Represents Restricted Stock Units ("RSUs") that will vest in 3 installments as follows: 28,000 shall vest on each of January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| July 28, 2022 Filed Aug 2, 2022 00:00 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 34,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-043769 · doc4.xml · nonDerivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,666 F1 · price: Represents Common Stock granted by the Issuer that vested on August 1, 2022. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:39 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 72,000 | $0.00 Strike: $13.89 | $0.00 |
DisclosureSEC source: 0001213900-22-000816 · ownership.xml · derivative · entry 2 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 72,000 shares Expires 2032-01-03 F2 · derivative.exercise_date: The Stock Option will vest in 4 installments as follows: 18,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:39 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 42,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-22-000816 · ownership.xml · nonDerivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,666 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 10,500 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:46 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 66,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-21-046411 · ownership.xml · nonDerivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,666 F1 · price: Restricted Stock Units ("RSUs") granted in February 2021 and vested upon achievement of certain vesting conditions. The RSUs convert into Issuer's common stock on a one-for-one basis. Read SEC document |
| February 03, 2021 Filed Feb 8, 2021 22:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $10.40 | $0.00 |
DisclosureSEC source: 0001213900-21-007501 · ownership.xml · derivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-02-03 F1 · kind: The Stock Option will vest in 4 equal installments as follows: 25,000 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024. F1 · derivative.exercise_date: The Stock Option will vest in 4 equal installments as follows: 25,000 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024. Read SEC document |
| January 08, 2020 Filed Jan 14, 2020 21:05 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001213900-20-000985 · ownership.xml · derivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-01-08 F1 · derivative.exercise_date: The Stock Option will vest in 4 installments as follows: 25,000 shall vest on each of December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 22:07 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 104,000 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001213900-19-018198 · ownership.xml · derivative · entry 2 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,000 Underlying: Common Stock · 104,000 shares Expires 2029-09-12 F1 · kind: The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on February 26, 2019 and provides for vesting in 4 equal installments of 26,000 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022. F1 · derivative.exercise_date: The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on February 26, 2019 and provides for vesting in 4 equal installments of 26,000 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:57 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 104,000 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001213900-19-003337 · ownership.xml · derivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,000 Underlying: Common Stock · 104,000 shares Expires 2029-02-26 F1 · derivative.exercise_date: The Stock Option will vest in 4 equal installments of 26,000 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022. Read SEC document |
| February 26, 2019 Filed Sep 16, 2019 22:07 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Disposition to issuerStock Option (right to buy) · Derivative | 104,000 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001213900-19-018198 · ownership.xml · derivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 104,000 shares Expires 2029-02-26 F1 · kind: The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on February 26, 2019 and provides for vesting in 4 equal installments of 26,000 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022. F1 · derivative.exercise_date: The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on February 26, 2019 and provides for vesting in 4 equal installments of 26,000 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 22:32 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 47,000 | $0.00 Strike: $8.14 | $0.00 |
DisclosureSEC source: 0001213900-18-001245 · f4013118kidronmiriam_oramed.xml · derivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires 2028-01-31 F1 · derivative.exercise_date: The Stock Option will vest in 4 equal installments of 11,750 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022. Read SEC document |
| August 02, 2017 Filed Aug 3, 2017 22:00 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | SaleCommon Stock | 89,636 | $8.50 | $761,906.00 |
DisclosureSEC source: 0001213900-17-008213 · f4080217kidron_oramed.xml · nonDerivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 F1 · shares: These shares were sold to Li Xiaopeng, a director of Oramed Pharmaceuticals Inc., and the reporting person used the proceeds in connection with a personal tax payment. F2 · balance_after: Consists of 75,000 shares of Common Stock underlying vested Restricted Stock Units that are issuable upon request. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 19:38 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 69,999 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001213900-17-007158 · f4063017mkidron_oramed.xml · derivative · entry 2 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,999 Underlying: Common Stock · 69,999 shares Expires 2027-06-30 F3 · derivative.exercise_date: The Stock Option will vest in 3 equal installments of 23,333 on each of December 31, 2017, December 31, 2018 and December 31, 2019. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 19:38 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-17-007158 · f4063017mkidron_oramed.xml · nonDerivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,636 F1 · shares: The shares vest immediately. F2 · balance_after: Consists of 164,636 shares of Common Stock underlying vested Restricted Stock Units that are issuable upon request. Read SEC document |
| April 19, 2017 Filed Apr 19, 2017 21:01 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | SaleCommon Stock | 52,814 | $6.33 | $334,312.62 |
DisclosureSEC source: 0001178913-17-001170 · zk1719828.xml · nonDerivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,636 F1 · shares: These shares were sold to Li Xiapeng, a director of Oramed Pharmaceuticals Inc. F2 · balance_after: Consists of 89,636 shares of Common Stock underlying vested Restricted Stock Units that are issuable upon request. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.